ortho-(1-naphthoyl)benzoic acid profile

ortho-(1-naphthoyl)benzoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	78723
CHEMBL ID	1605748
SCHEMBL ID	6051351
MeSH ID	M0296392

Synonym
einecs 225-702-6
nsc 59936
2-(1-naphthoyl)benzoic acid
nsc-59936
5018-87-1
benzoic acid, 2-(1-naphthalenylcarbonyl)-
benzoic acid, o-1-naphthoyl-
nsc59936
2-(naphthalen-1-ylcarbonyl)benzoic acid
STK366693
NCIOPEN2_002520
MLS001195141 ,
smr000554507
AKOS001593217
2-(naphthalene-1-carbonyl)benzoic acid
NCGC00245812-01
CHEMBL1605748
HMS2857K14
FT-0608377
DTXSID3063679
SCHEMBL6051351
OXCYAVHGYGKEJY-UHFFFAOYSA-N
2-naphthalen-1-ylcarbonylbenzoic acid
2-[1-naphthalenyl(oxo)methyl]benzoic acid
bdbm52026
cid_78723
2-(naphthoyl)benzoic acid
SR-01000391835-1
sr-01000391835
2-(1-naphthalenylcarbonyl)benzoic acid
2-(a-naphthoyl)benzoic acid
2-(1-naphthoyl)benzoicacid
ortho-(1-naphthoyl)benzoic acid
2-(naphthalene-1-carbonyl)-benzoic acid
2-(naphthoyl)benzoicacid
mfcd00014313
Z9UWM9S7B3

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Smad3	Homo sapiens (human)	Potency	5.6234	0.0052	7.8098	29.0929	AID588855
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	70.7946	0.3548	28.0659	89.1251	AID504847
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	6.3096	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
metallo beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	8.4615	0.0339	2.9100	6.2480	AID1919; AID1926
metallo-beta-lactamase IMP-1	Pseudomonas aeruginosa	IC50 (µMol)	59.6400	3.2410	5.9685	8.6960	AID1920; AID1927
M-phase inducer phosphatase 2	Homo sapiens (human)	Ki	69.0000	0.0950	0.0950	0.0950	AID1516475
Beta lactamase (plasmid)	Pseudomonas aeruginosa	IC50 (µMol)	59.6400	0.7091	5.0549	7.7510	AID1925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G2/M transition of mitotic cell cycle	M-phase inducer phosphatase 2	Homo sapiens (human)
mitotic cell cycle	M-phase inducer phosphatase 2	Homo sapiens (human)
oocyte maturation	M-phase inducer phosphatase 2	Homo sapiens (human)
protein phosphorylation	M-phase inducer phosphatase 2	Homo sapiens (human)
female meiosis I	M-phase inducer phosphatase 2	Homo sapiens (human)
positive regulation of cell population proliferation	M-phase inducer phosphatase 2	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	M-phase inducer phosphatase 2	Homo sapiens (human)
positive regulation of cytokinesis	M-phase inducer phosphatase 2	Homo sapiens (human)
positive regulation of mitotic cell cycle	M-phase inducer phosphatase 2	Homo sapiens (human)
cell division	M-phase inducer phosphatase 2	Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycle	M-phase inducer phosphatase 2	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
phosphoprotein phosphatase activity	M-phase inducer phosphatase 2	Homo sapiens (human)
protein tyrosine phosphatase activity	M-phase inducer phosphatase 2	Homo sapiens (human)
protein binding	M-phase inducer phosphatase 2	Homo sapiens (human)
protein kinase binding	M-phase inducer phosphatase 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
spindle pole	M-phase inducer phosphatase 2	Homo sapiens (human)
nucleoplasm	M-phase inducer phosphatase 2	Homo sapiens (human)
centrosome	M-phase inducer phosphatase 2	Homo sapiens (human)
cytosol	M-phase inducer phosphatase 2	Homo sapiens (human)
nucleus	M-phase inducer phosphatase 2	Homo sapiens (human)
cytoplasm	M-phase inducer phosphatase 2	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID673449	Inhibition of recombinant phosphatase activity of Cdc25B catalytic domain expressed in Escherichia coli BL21(DE3) using OMFP as substrate at 50 uM by spectrofluorimetric analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
AID1516473	Inhibition of N-terminal His6-tagged human CDC25B (377 to 550 residues) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Vmax using OMFP as substrate by double reciprocal Lineweaver-Burk plot analysis	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines.
AID1516475	Mixed inhibition of N-terminal His6-tagged human CDC25B (377 to 550 residues) expressed in Escherichia coli BL21(DE3) cells using OMFP as substrate by double reciprocal Lineweaver-Burk plot analysis	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	1 (12.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
1-naphthylphenylamine N-phenyl-1-naphthylamine: RN given refers to 1-naphthylamine cpd; structure	2.21	1	0	naphthalenes
sulisobenzone [no description available]	2.07	1	0	benzophenones

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Malignant Melanoma [description not available]	2.21	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.21	1

ortho-(1-naphthoyl)benzoic acid

Description

Cross-References

Synonyms (37)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Biological Processes (29)

Molecular Functions (13)

Ceullar Components (13)

Bioassays (16)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.63

Study Types

ortho-(1-naphthoyl)benzoic acid

Description

Cross-References

Synonyms (37)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Biological Processes (29)

Molecular Functions (13)

Ceullar Components (13)

Bioassays (16)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.63

Study Types

Related Drugs (2)

Related Conditions (4)